![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update PR Newswire DUBLIN, Aug. 5, 2024 Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million...
Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN, July 25, 2024 DUBLIN, July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will...
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN, July 22, 2024 DUBLIN, July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 99.85 | 99.85 | 99.5 | 13 | 99.75 | DE |
260 | 0 | 0 | 99.85 | 99.85 | 99.5 | 13 | 99.75 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions